Award recognizes the groundbreaking science of Dupixent and its transformational impact on multiple rare and common allergic and atopic conditions First and only therapy to specifically target the ...
UCB, a global biopharmaceutical company, today announced three-year data from the BE HEARD trials for BIMZELX® (bimekizumab-bkzx) in moderate-to-severe hidradenitis suppurativa (HS). BIMZELX, the ...
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of four posters in patients with hepatorenal syndrome (HRS), including a Poster of Distinction, at The ...
Mallinckrodt plc, a global specialty pharmaceutical company, today announced the presentation of two posters on terlipressin in patients with hepatorenal syndrome-acute kidney injury (HRS-AKI), at ...
UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting new data highlighting insights on patient outcomes with rozanolixizumab and zilucoplan for ...
Merck and Eisai Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma ...
Q3 2025 Earnings Call Transcript October 27, 2025 BioMarin Pharmaceutical Inc. misses on earnings expectations. Reported EPS is $-1.09923 EPS, expectations were $0.01. Operator: Hello, and welcome to ...
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or ...
Early broadly neutralising antibody responses against the E1E2 glycoprotein seem to be important for preventing persistence ...
Reviewers viewed the targeting of TFAM as innovative and the study's conclusions as potentially important (especially the effects on inflammation). However, the lack of evidence for a direct effect of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback